# PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer

*PRI Rank #6 · Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026/rank-6*

| Field | Value |
| --- | --- |
| Rank | #6 |
| 18m citations | 71 |
| Journal | Journal of Clinical Oncology |
| Year | 2024 |
| DOI | 10.1200/jco.23.01940 |
| Corresponding authors | Erica L Mayer |
| Institution | Dana-Farber Cancer Institute, United States |

**Ranking page:** [Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026](https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026)

**Paper link:** [10.1200/jco.23.01940](https://doi.org/10.1200/jco.23.01940)

## Topics

CDK4/6 inhibitor · palbociclib · fulvestrant · avelumab · hormone receptor-positive breast cancer · HER2-negative metastatic breast cancer · aromatase inhibitor · immune checkpoint inhibitors · progression-free survival · ESR1 alterations · PIK3CA alterations · CDK4/6 inhibitor resistance · endocrine therapy · post-progression treatment · de novo metastatic breast cancer

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026. https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026. Accessed 2026-10-28.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```